About ProMIS Neurosciences (PMN)

ProMIS Neurosciences, Inc. (PMN) is a biotechnology company focused on discovering and developing precision medicine therapeutics for neurodegenerative diseases, with a particular emphasis on Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The company's proprietary discovery platform utilizes its unique understanding of misfolded proteins to identify therapeutic targets that are specifically linked to these diseases. By targeting the toxic oligomers of misfolded proteins, ProMIS aims to develop highly selective antibody-based therapies that can halt the progression of neurodegeneration and ultimately improve patient outcomes.

One of ProMIS' key innovations is its use of computational algorithms to predict the specific regions of misfolded proteins that are likely to be toxic and targetable by therapeutic antibodies. This approach enables the company to design and develop highly selective antibodies that bind exclusively to these toxic species, while avoiding binding to harmless forms of the protein. This level of specificity is crucial for achieving therapeutic efficacy while minimizing the risk of unwanted side effects.